Michael W. George

Mike George currently serves on the ClearPath Diagnostics Board of Directors. From 1998 to 2001, Mike served as the President, COO and CEO of UroCor, Inc. a 430 employee laboratory that specialized in oncology products and services for Urologists. Prior to Mike’s arrival, the company struggled to grow, was consistently unprofitable and was embroiled in a Department of Justice investigation into Medicare Fraud and Abuse.  Mike successfully negotiated a settlement with the Department of Justice and returned the company to profitable growth. During Mike’s tenure the company increased revenue by 50% to $60 million and saw the stock price appreciate more than 600% with market capitalization growing from $28 million to $190 million.  In addition to driving rapid growth, Mike successfully installed infrastructure and financial discipline to ensure continued revenue and earnings growth.  In 2001, the company was sold to DIANON.

In addition to Mike’s success with UroCor he has previously served as President of Elan Pharmaceuticals, a 1,400-person organization producing $900 million in annual revenues, serving therapeutic areas including neurological, dermatological and antibiotics.  Most recently, Mike has successfully led a turnaround of two struggling CROs (Contract Research Organizations). The first turnaround was DermTech International, a CRO specializing in dermatology clinical research studies with $10.5 million per year in annual sales. Subsequently, Mike led the organizational restructuring of aaiPharma, a $200 million per year pharmaceutical company and CRO in a turnaround situation due to inconsistent cash flow, Department of Justice and SEC investigations and an extensive debt load.Mike began his executive career with The DuPont Merck Pharmaceutical Company.  Mike held roles of increasing responsibility between 1989 and 1998, ultimately serving as Executive Vice President, Administration and reporting directly to the CEO.  Prior to becoming an Executive Vice President, Mike served as President of North America where he had management responsibility for a business with $700 million in revenue, 750 employees and a $150 million expense budget. During his tenure as President, Mike grew revenues of a mature cardiovascular and CNS product line by more than 300% and earnings by more than 500%.Mike earned a B.S., in Business Administration from Central Missouri State University and a M.B.A. from the University of Southern New Hampshire.